{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:33:25Z","timestamp":1793140405235,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jns.2024.123290","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T17:10:51Z","timestamp":1730567451000},"page":"123290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy of Radicava\u00ae IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial"],"prefix":"10.1016","volume":"467","author":[{"given":"Erik P.","family":"Pioro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Rix","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Apple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123290_bb0005","series-title":"Prescribing Information","author":"Rilutek\u00ae (riluzole)","year":"2016"},{"key":"10.1016\/j.jns.2024.123290_bb0010","series-title":"Radicava\u00ae (edaravone) IV and Radicava ORS\u00ae (edaravone) oral suspension. Prescribing Information","year":"2022"},{"key":"10.1016\/j.jns.2024.123290_bb0015","series-title":"Prescribing Information","author":"QALSODY\u00ae (tofersen) Injection","year":"2023"},{"key":"10.1016\/j.jns.2024.123290_bb0020","series-title":"Relyvrio\u00ae (Sodium Phenylbutyrate and Taurursodiol). Prescribing Information","year":"2022"},{"key":"10.1016\/j.jns.2024.123290_bb0025","author":"Amylyx Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.jns.2024.123290_bb0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Edaravone (MCI-186) ALS 19 study group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Writing Group","year":"2017","journal-title":"Lancet Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2024.123290_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/21678421.2017.1364269","article-title":"Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","author":"Writing Group on Behalf of the Edaravone ALS 19 Study Group","year":"2017","journal-title":"Amyotr. Later. Scler Frontotemporal. Degener."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2024.123290_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/21678421.2017.1365372","article-title":"Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis","volume":"18","author":"Takei","year":"2017","journal-title":"Amyotr. Later. Scler Frontotemporal. Degener."},{"issue":"2","key":"10.1016\/j.jns.2024.123290_bb0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mus.26740","article-title":"Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of study 19 (MCI186-19)","volume":"61","author":"Shefner","year":"2020","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2024.123290_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258614","article-title":"Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of study 19 (MCI186-19) [clinical trial NCT01492686]","volume":"17","author":"Brooks","year":"2022","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1016\/j.jns.2024.123290_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.jns.2024.123290_bb0060","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1212\/01.WNL.0000144345.49510.4E","article-title":"Functional outcome measures as clinical trial endpoints in ALS","volume":"63","author":"Traynor","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2024.123290_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtha.2022.11.013","article-title":"Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis","volume":"21","author":"de Winter","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.jns.2024.123290_bb0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s43441-022-00459-0","article-title":"A proposal for post hoc subgroup analysis in support of regulatory submission","volume":"57","author":"Liu","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.jns.2024.123290_bb0075","series-title":"European Medicines Agency\/Committee for Medicinal Products for Human Use","article-title":"Guideline on the investigation of subgroups in confirmatory clinical trials","author":"European Medicines Agency","year":"2019"},{"issue":"3","key":"10.1016\/j.jns.2024.123290_bb0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s43441-019-00082-6","article-title":"A systematic approach for post hoc subgroup analyses with applications in clinical case studies","volume":"54","author":"Muysers","year":"2020","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.jns.2024.123290_bb0085","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3389\/fpsyg.2019.01214","article-title":"The application of latent class analysis for investigating population child mental health: a systematic review","volume":"10","author":"Petersen","year":"2019","journal-title":"Front. Psychol."},{"issue":"4","key":"10.1016\/j.jns.2024.123290_bb0090","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10705510701575396","article-title":"Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study","volume":"14","author":"Nylund","year":"2007","journal-title":"Struct. Equ. Model."},{"issue":"4","key":"10.1016\/j.jns.2024.123290_bb0095","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/10705511.2014.919819","article-title":"Effect size, statistical power and sample size requirements for the bootstrap likelihood ratio test in latent class analysis","volume":"21","author":"Dziak","year":"2014","journal-title":"Struct. Equ. Model."},{"issue":"3","key":"10.1016\/j.jns.2024.123290_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1467-9876.2012.01066.x","article-title":"How to find an appropriate clustering for mixed-type variables with application to socio-economic stratification","volume":"62","author":"Hennig","year":"2013","journal-title":"J. R. Stat. Soc.: Ser. C: Appl. Stat."},{"issue":"4","key":"10.1016\/j.jns.2024.123290_bb0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1037\/tps0000176","article-title":"Ten frequently asked questions about latent class analysis","volume":"4","author":"Nylund-Gibson","year":"2018","journal-title":"Transl. Issues Psychol. Sci."},{"key":"10.1016\/j.jns.2024.123290_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-10-1","article-title":"A tutorial on pilot studies: the what, why and how","volume":"10","author":"Thabane","year":"2010","journal-title":"BMC Med. Res. Methodol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2024.123290_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/21678421.2013.838970","article-title":"Pooled resource open-access ALS clinical trials consortium. Amyotrophic lateral sclerosis disease progression model","volume":"15","author":"Gomeni","year":"2014","journal-title":"Amyotr. Later. Scler Frontotemporal. Degener."},{"issue":"19","key":"10.1016\/j.jns.2024.123290_bb0120","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.0000000000000951","article-title":"The PRO-ACT database: design, initial analyses, and predictive features","volume":"83","author":"Atassi","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2024.123290_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174925","article-title":"Predicting functional decline and survival in amyotrophic lateral sclerosis","volume":"12","author":"Ong","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jns.2024.123290_bb0130","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mus.26042","article-title":"Pooled resource open-access ALS clinical trials consortium. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort","volume":"57","author":"Thakore","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123290_bb0135","first-page":"207","article-title":"Missing data imputation in the electronic health record using deeply learned autoencoders","volume":"22","author":"Beaulieu-Jones","year":"2017","journal-title":"Pac. Symp. Biocomput."},{"key":"10.1016\/j.jns.2024.123290_bb0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s43588-022-00299-w","article-title":"Identifying patterns of ALS progression from sparse longitudinal data","volume":"2","author":"Ramamoorthy","year":"2022","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.jns.2024.123290_bb0145","article-title":"Unsupervised machine-learning identifies clinically distinct subtypes of ALS that reflect different genetic architectures and biological mechanisms","author":"Spargo","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jns.2024.123290_bb0150","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/2041-210X.13434","article-title":"Robustness of linear mixed-effects models to violations of distributional assumptions","volume":"11","author":"Schielzeth","year":"2020","journal-title":"Methods Ecol. Evol."},{"issue":"21","key":"10.1016\/j.jns.2024.123290_bb0155","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.2016.3676","article-title":"The potential for postrandomization confounding in randomized clinical trials","volume":"315","author":"Manson","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jns.2024.123290_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/157488407780598162","article-title":"Clinical trials: how to assess confounding and why so","volume":"2","author":"Cleophas","year":"2007","journal-title":"Curr. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.jns.2024.123290_bb0165","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/sim.4131","article-title":"A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial","volume":"30","author":"Altstein","year":"2011","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.123290_bb0170","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1468-1331.2008.02434.x","article-title":"Measuring function in advanced ALS: validation of ALSFRS-EX extension items","volume":"16","author":"Wicks","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"Spec Iss 1","key":"10.1016\/j.jns.2024.123290_bb0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/BrImp.2017.31","article-title":"An introduction to item response theory and Rasch analysis of the eating assessment tool (EAT-10)","volume":"19","author":"Kean","year":"2018","journal-title":"Brain Impair."},{"key":"10.1016\/j.jns.2024.123290_bb0180","first-page":"1","article-title":"Interpreting results from Rasch analysis 1. The \u201cmost likely\u201d measures coming from the model","author":"Tesio","year":"2023","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.jns.2024.123290_bb0185","first-page":"1","article-title":"Interpreting results from Rasch analysis 2. Advanced model applications and the data-model fit assessment","author":"Tesio","year":"2023","journal-title":"Disabil. Rehabil."},{"issue":"10","key":"10.1016\/j.jns.2024.123290_bb0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jns.2024.123290_bb0195","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.123290_bb0200","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","article-title":"Progression in ALS is not linear but is curvilinear","volume":"257","author":"Gordon","year":"2010","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2024.123290_bb0205","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1164\/rccm.201902-0344OC","article-title":"Classifying patients with amyotrophic lateral sclerosis by changes in FVC. A group-based trajectory analysis","volume":"200","author":"Ackrivo","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jns.2024.123290_bb0210","series-title":"Amyotroph Lateral Scler Frontotemporal Degener","article-title":"ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline","volume":"7","author":"Hamatani","year":"2024"},{"key":"10.1016\/j.jns.2024.123290_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117054","article-title":"Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis","volume":"417","author":"Richards","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2024.123290_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1212\/WNL.0000000000200799","article-title":"Hastening the diagnosis of amyotrophic lateral sclerosis","volume":"99","author":"Mitsumoto","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2024.123290_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","article-title":"Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model","volume":"17","author":"Westeneng","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123290_bb0230","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13063-020-04254-w","article-title":"Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events","volume":"21","author":"Fanaroff","year":"2020","journal-title":"Trials"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400426X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400426X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T09:24:14Z","timestamp":1733909054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2400426X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S0022510X2400426X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123290","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Radicava\u00ae IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mitsubishi Tanabe Pharma America, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123290"}}